KORU Medical Systems (NASDAQ:KRMD) Raised to “Strong-Buy” at B. Riley

KORU Medical Systems (NASDAQ:KRMD) was upgraded by equities research analysts at B. Riley to a “strong-buy” rating in a note issued to investors on Thursday,Zacks.com reports.

A number of other research firms have also recently weighed in on KRMD. Canaccord Genuity Group lifted their target price on shares of KORU Medical Systems from $3.00 to $4.00 and gave the company a “buy” rating in a research note on Thursday, November 14th. Piper Sandler restated a “neutral” rating and issued a $4.50 price objective on shares of KORU Medical Systems in a research report on Friday, February 14th. Lake Street Capital increased their target price on KORU Medical Systems from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Tuesday, January 14th. Finally, Craig Hallum boosted their price target on KORU Medical Systems from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Friday, January 17th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $4.70.

KORU Medical Systems Price Performance

NASDAQ KRMD opened at $2.77 on Thursday. The company has a current ratio of 2.99, a quick ratio of 2.37 and a debt-to-equity ratio of 0.01. KORU Medical Systems has a 12 month low of $2.04 and a 12 month high of $5.05. The stock has a market cap of $126.97 million, a price-to-earnings ratio of -11.08 and a beta of 0.74. The company’s 50 day moving average is $3.94 and its two-hundred day moving average is $3.39.

Institutional Investors Weigh In On KORU Medical Systems

Several large investors have recently made changes to their positions in KRMD. XTX Topco Ltd bought a new position in KORU Medical Systems during the third quarter valued at approximately $34,000. JPMorgan Chase & Co. boosted its position in shares of KORU Medical Systems by 2,770.7% during the 4th quarter. JPMorgan Chase & Co. now owns 17,712 shares of the company’s stock valued at $68,000 after acquiring an additional 17,095 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of KORU Medical Systems in the fourth quarter valued at $73,000. Vivaldi Capital Management LP bought a new stake in KORU Medical Systems in the fourth quarter worth $82,000. Finally, Balyasny Asset Management L.P. purchased a new stake in KORU Medical Systems during the fourth quarter valued at $84,000. 58.60% of the stock is owned by institutional investors.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria.